PHVS - Pharvaris N.V. Common Stock

Pharvaris N.V. (PHVS)

NGS · Common · CUSIP N69605108

Last Price•••.••

Current Yield•.••%

Yield to Call•.••%

Yield to Worst•.••%

Free registration unlocks the quote, yield calculations, price chart and full fundamentals for PHVS and every other security on QuantumOnline.

Overview Financials 🔒 Earnings 🔒 Dividends 🔒 Analysts 🔒 Ownership 🔒 ESG 🔒 Technicals 🔒

🔒

Price chart and 15 days of daily prices

Candlestick chart with moving averages, Bollinger bands and MACD. Register free to view.

Security Profile

Security Type: Common Stock
CUSIP: N69605108
Market Cap: Micro Cap
IPO: 2/5/2021 · $20.00/share

Links: Home Page Investor Relations News

Business: Pharvaris N.V. is a clinical-stage company focused on bringing oral bradykinin B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules. PHA121, Pharvaris’ lead drug candidate, is a novel, potent small-molecule bradykinin B2 receptor antagonist.

Company Contact

CEO: Berndt Modig
CFO: Anna Nijdam
Investor Relations: Chad Rubin, Solebury Trout · crubin@soleburytrout.com
Email Form: Contact Form »
SEC EDGAR Filings: View filings »